Literature DB >> 30141013

Generation of Recombinant Monoclonal Antibodies from Single B Cells Isolated from Synovial Tissue of Rheumatoid Arthritis Patients.

Elisa Corsiero1, Lucas Jagemann2, Michele Bombardieri2, Costantino Pitzalis2.   

Abstract

Ectopic lymphoid structure (ELS) can form in the target tissues of patients with chronic inflammatory autoimmune diseases such as rheumatoid arthritis (RA) and Sjögren's syndrome (SS). Although it is still not clear why ELS form only in a subset of patients, it is well known that these structures can acquire features of ectopic germinal centers and contribute actively to the production of autoantibodies. Here, we describe a method to generate recombinant monoclonal antibodies from single ELS+ synovial tissue B cells obtained from RA patients. This chapter gives a detailed description of the method beginning from the mononuclear cell preparation from RA synovial tissue, single-cell sort of B cells by flow cytometry, amplification of the immunoglobulin (Ig) genes (both heavy- and light-chain genes) by PCR, and subsequent Ig gene expression vector cloning for full recombinant IgG1 monoclonal antibody (rmAb) production in vitro. The recombinant mAbs generated can be then characterized for (1) analysis of the Ig gene repertoires for clonal studies, (2) immunoreactivity profile, and (3) functional studies both in vitro and in vivo.

Entities:  

Keywords:  Cloning; Ectopic lymphoid structure; Monoclonal antibody; Rheumatoid arthritis; Single B cell; Single-cell-nested PCR; Synovial tissue

Mesh:

Substances:

Year:  2018        PMID: 30141013     DOI: 10.1007/978-1-4939-8709-2_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  H and L Chain Affinity Maturation and/or Fab N-Glycosylation Influence Immunoreactivity toward Neutrophil Extracellular Trap Antigens in Rheumatoid Arthritis Synovial B Cell Clones.

Authors:  Elisa Corsiero; Emanuela Carlotti; Lucas Jagemann; Mauro Perretti; Costantino Pitzalis; Michele Bombardieri
Journal:  J Immunol       Date:  2020-03-27       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.